Continuous production of endothelium-derived nitric oxide (NO) in peripheral vessels has been shown to modulate vascular resistance and blood pressure. NO is also formed in the brain upon activation of glutamate receptors, which are thought to mediate central autonomic reflexes. In the present study we assessed whether NO plays a role in central autonomic regulation. For this, we have investigated the effects of NG_methyl-L-arginine (NMA), a selective inhibitor of NO synthesis from L-arginine, on sympathetic renal nerve activity (RNA), blood pressure, and heart rate in the anesthetized rat. NMA elicited a dose-dependent sustained increase in blood pressure (approximately 20 and 30 mm Hg, 5 minutes after 10 and 50 pumol/kg i.v., respectively). Heart rate and RNA decreased transiently (15 beats per minute and 40%, respectively); RNA subsequently increased (100%1) while blood pressure remained elevated. Baroreceptor deafferentation markedly altered these responses to NMA; the transient decreases in heart rate and RNA were abolished, whereas the increases in RNA and blood pressure were significantly potentiated. After spinal C-1-C-2 transection, there was no increase in RNA, and blood pressure increased to a smaller extent. L-Arginine blocked the NMA-induced increases in blood pressure release from peripheral vessels elicits a continuous vasorelaxant action in vivo. EDRF is also produced in the brain; Garthwaite et a112 found that, on activation of L-glutamate receptors, rat cerebellar cells release EDRF/NO, which in turn elevates intracellular cGMP. Additional investigations have provided evidence for the enzymatic formation of NO from L-arginine in cytosol from rat forebrain synaptosomes'3 and bovine brain.14 More recently, evidence was presented in favor of the view that serotonin induces EDRF/NO production in NG108-15 mouse neuroblastoma-rat glioma hybrid cells.15 These observations have raised the possibility that the EDRF/NOcGMP system may function as an important signal transduction system in the brain.16 Indeed, new evidence demonstrating that NO synthase is present in discrete neuronal populations further implies a neural messenger role for NO.17 Since L-glutamate and serotonin receptors have been implicated in central autonomic reflexes,18 it is conceivable that sympathetic nerve activity would be modulated by EDRF/NO. If so, blocking EDRF/NO production in the brain with NMA might be expected to alter
N itric oxide (NO), or a molecule capable of forming NO, is a major endothelium-derived relaxing factor (EDRF)'-4; it is synthesized from L-arginine by an enzymatic pathway that is selectively inhibited by N0-methyl-L-arginine (NMA).5-7 The intravenous administration of NMA to guinea pigs,8 rabbits,9 rats,10 and dogs11 elicits a sustained increase in arterial blood pressure (BP); L-arginine reverses this response. These findings indicate that basal EDRF/NO release from peripheral vessels elicits a continuous vasorelaxant action in vivo.
EDRF is also produced in the brain; Garthwaite et a112 found that, on activation of L-glutamate receptors, rat cerebellar cells release EDRF/NO, which in turn elevates intracellular cGMP. Additional investigations have provided evidence for the enzymatic formation of NO from L-arginine in cytosol from rat forebrain synaptosomes'3 and bovine brain.14 More recently, evidence was presented in favor of the view that serotonin induces EDRF/NO production in NG108-15 mouse neuroblastoma-rat glioma hybrid cells.15 These observations have raised the possibility that the EDRF/NOcGMP system may function as an important signal transduction system in the brain. 16 Figure 3 ). A value of p<0.05 was considered statistically significant.
Results
Intravenous bolus administration of NMA umoVkg) to anesthetized rats elicited a dose-dependent increase in BP that lasted > 10 minutes (Figures 1 and 2 ). The pressor response to NMA was associated with a decrease in HR and a biphasic change in renal nerve activity (RNA) (Figures 1 and 2 ). RNA decreased initially until the concomitant increase in BP reached a plateau and subsequently increased beyond the pre-NMA level while BP remained elevated (Figures 1 and 2 ).
After total deafferentation (i.e., vagotomy plus sinoaortic denervation), the pressor response to NMA was potentiated, and no decrease in HR occurred (Figure 1 ; also compare columns a and b in Figure 3 ). Moreover, in the deafferentated rat, there was no initial decrease in RNA but only a monophasic increase (Figure 1 ; also compare columns a and b in Figure 3 ). Spinal transection in the deafferentated rat abolished the NMA-induced increase in RNA (compare columns b and c in Figure 3 ). Changes in adrenal nerve activity in response to NMA in the deafferentated rat were similar to those in RNA: the percent increase at 1, 5, and 10 minutes after the administration of an intravenous bolus of NMA (50 ,umol/kg) was 0±+10%, or MMA (mn) saline n *g*^C1 1**** 63+19%, and 41+10%, respectively, for RNA (n=6) and 2±6%, 53+24%, and 26+14%, respectively, for adrenal nerve activity (n=10).
We next investigated the effects of L-arginine pretreatment on the changes induced by NMA. Intravenous bolus administration of L-arginine to the deafferentated rat resulted in transient decreases in BP, HR, and RNA; these parameters returned to baseline within 5 minutes after the 50 ,umol/kg dose of L-arginine and within 10 minutes after the 500 ,tmol/kg dose. When NMA was injected by intravenous bolus into deafferentated rats pretreated for 5 and 10 minutes with 50 and 500 umol/kg L-arginine, respectively, the pressor response to NMA was inhibited (Figure 4) . Indeed, L-arginine converted the NMA-induced increase in RNA in the deafferentated rat to a decrease (Figure 4) . Discussion NMA elicited a dose-dependent increase in arterial BP and a decrease in HR in the intact a-chloralose/ urethane-anesthetized rat. Similar changes were previously reported to occur in barbiturate-anesthetized guinea pigs,8 rabbits,9 rats,10 and dogs." In contrast, an NMA-induced increase in RNA had not been described previously. We observed an initial transient decrease in RNA, followed by a substantial increase despite a continuous elevation in BP. Inasmuch as an elevation in BP by NMA should elicit a reflex decrease in sympathetic outflow, which would complicate our analysis of NMA action on RNA, we sought to eliminate this reflex by total deafferentation. Abolition of the baroreceptor reflex uncovered a slow-onset monophasic increase in RNA and potentiated the increase in BP seen with NMA; both effects were abolished by spinal transection. These findings indicate that NMA crosses the bloodbrain barrier and directly stimulates sympathetic nerve activity.
Since NO/EDRF may be capable of modulating efferent neurotransmission at neuronal junctions,16 the site of the NMA-induced increase in RNA could be either at the spinal level or the celiac ganglion. However, spinal transection between C-1 and C-2 abolished the increase in postganglionic RNA caused by NMA. Furthermore, in the deafferentated rat, NMA elicited similar increases in postganglionic (renal) and preganglionic (adrenal) nerve activity. Accordingly, the site of the neural action of NMA appears to be central rather than peripheral; indeed, we have obtained preliminary evidence of a pressor effect of NMA injected into the cisterna magna at doses lower than those shown to increase BP upon intravenous administration. 22 To investigate whether the effects of NMA on RNA were due to specific inhibition of EDRF/NO synthesis, the deafferentated rat was pretreated with L-arginine. L-Arginine elicited a transient dose-dependent decrease in RNA associated with a small reduction in BP and HR at the higher dose tested (500 gmol/kg). It is conceivable that these effects of L-arginine arise from an enhanced NO synthesis in the brain. We found that the administration of NMA to L-arginine-pretreated rats (after the direct effects of L-arginine had waned) failed to elicit an increase in RNA (see Figure 4) . We interpret 
